BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 119 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,524 | -74.0% | 21,551 | -31.5% | 0.00% | – |
| Q2 2023 | $209,497 | -37.5% | 31,456 | +75.1% | 0.00% | – |
| Q1 2023 | $335,190 | +11.6% | 17,963 | +28.5% | 0.00% | – |
| Q4 2022 | $300,290 | +79.8% | 13,980 | -1.1% | 0.00% | – |
| Q3 2022 | $167,000 | -9.7% | 14,130 | +0.6% | 0.00% | – |
| Q2 2022 | $185,000 | -38.9% | 14,041 | -3.2% | 0.00% | – |
| Q1 2022 | $303,000 | +9.8% | 14,500 | +6.8% | 0.00% | – |
| Q4 2021 | $276,000 | -32.7% | 13,574 | +0.5% | 0.00% | – |
| Q3 2021 | $410,000 | +13.6% | 13,511 | +8.6% | 0.00% | – |
| Q2 2021 | $361,000 | -32.8% | 12,443 | -0.1% | 0.00% | – |
| Q1 2021 | $537,000 | -76.2% | 12,450 | -74.5% | 0.00% | -100.0% |
| Q4 2020 | $2,254,000 | -12.4% | 48,751 | -17.9% | 0.00% | -50.0% |
| Q3 2020 | $2,574,000 | +1.2% | 59,380 | +23.8% | 0.00% | 0.0% |
| Q2 2020 | $2,543,000 | – | 47,982 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |